Evidence map›Paper›PMID 39472454›Full record

ArticleScientific reports2024

FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients.

Marwa A Abdel-Wahed, Ghada Sadek Sabbour, Amira I Hamed, Mohammed Sabry El Kady, Shaimaa Khalil Mohammed, Menat Allah Ali Mahmoud Shaaban

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Association ofFrontiers in immunology · 2025
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marwa A Abdel-WahedDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, 38 Abbassyia Square, Cairo, Egypt. marrwa_ali3110@yahoo.com.
Ghada Sadek SabbourDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, 38 Abbassyia Square, Cairo, Egypt.
Amira I HamedDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, 38 Abbassyia Square, Cairo, Egypt.
Mohammed Sabry El KadyDepartment of Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Shaimaa Khalil MohammedDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, 38 Abbassyia Square, Cairo, Egypt.
Menat Allah Ali Mahmoud ShaabanDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, 38 Abbassyia Square, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is considered a multifactorial disease, with genetic factors playing an important role in diagnosis and treatment. FCGR3A encodes the receptor for the Fc portion of immunoglobulin G that has been linked to the trastuzumab response. Our study aimed to investigate the association of FCGR3A-V158F gene polymorphism with breast cancer and to evaluate the impact of FCGR3A-V158F gene polymorphism on trastuzumab response in HER2-positive breast cancer patients. The study was conducted on eighty breast cancer patients who were collected from the Department of Oncology at Ain Shams University Hospitals; in addition, twenty age-matched healthy subjects were taken as a healthy control group. Patients were further sub-classified according to their responses. The study showed that there were no statistically significant differences between patients and controls regarding FCGR3A-V158F gene polymorphism genotypes. However, there was a significant association between the concordance of this polymorphism and the response to trastuzumab therapy among the patient's group. V/V is associated with better treatment response and overall survival (OS) compared to F/V and F/F alleles. Assessment of FCGR3A-V158F gene polymorphism might be useful in making a treatment decision in HER2-positive breast cancer patients.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesPolymorphism, Single NucleotideReceptors, IgGTrastuzumabAdultAgedAllelesAntineoplastic Agents, ImmunologicalCase-Control StudiesFemaleGenotypeHumansMiddle AgedTreatment OutcomeAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFCGR3A protein, humanReceptors, IgGTrastuzumabFCGR3AGene polymorphismTrastuzumab

Identifiers

PMID39472454
PMCPMC11522560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.